Skip to main
CGON

CGON Stock Forecast & Price Target

CGON Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CG Oncology is advancing a best-in-class immunotherapy agent capable of achieving market-leading share across the NMIBC space. With updates on their Phase 3 PIVOT-006 trial timing and completing the cretoBLA in HR-NMIBC in 4Q, the prospects for CG Oncology look positive and the company's financials show increasing spend with a strong cash position.

Bears say

CG Oncology is a clinical biopharmaceutical company that is developing an intravesically delivered immunotherapy agent for bladder cancer. While they have promising trials and potential for significant revenue and market potential in the future, their main focus, PIVOT-006, is facing challenges and their pipeline additions may not be enough to outweigh any setbacks. It is important to closely monitor their trial data and future developments in order to have a more accurate outlook on the company's potential success in the competitive bladder cancer market.

CGON has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CG oncology Inc (CGON) Forecast

Analysts have given CGON a Buy based on their latest research and market trends.

According to 7 analysts, CGON has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CG oncology Inc (CGON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.